-
International Coagulation Meeting (ISTH 2013): Highlights
Stephan Moll, MD writes… A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013. The clinically relevant highlights about thrombosis and anticoagulation are summarized below.
-
Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants
There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…
-
Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants
There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1]. This…
-
Starting Pradaxa – Checklist
-
Starting Pradaxa? – Checklist
What topics do you need to discuss with your physican or anticoagulation clinic pharmacist or nurse when you are considering starting Pradaxa (Dabigatran)? A structured, bulleted checklist may be helpful for the discussion, to make sure that all relevant points are addressed. A suggested list is here.
-
Pradaxa – What Your Physician/Hospital Wants to Know
If you are considering to start therapy with the new oral “blood thinner” Pradaxa®, there are a few safety nets that your local hospital and physician may want to establish to make therapy as safe as possible for you. Issues to be addressed are (a) dosing, (b) management of major bleeding, (c) interruption of therapy…
-
Pradaxa (Dabigatran) – Hospital Guideline
The new oral anticoagulant Pradaxa® (Dabigatran) is increasingly being used as an alternative to warfarin. A number of practical management questions are now encountered by the physician, pharmacist, or other health care professional taking care of the patient on Pradaxa®, such as (a) dosing in renal impairment, (b) conversion of a patient on warfarin…
-
Pradaxa: Interruption for Colonoscopies, Dental Procedures, Surgery, etc.
When to stop the drug – General comments The patient on Pradaxa® (Dabigatran) may need interruption of therapy for dental work, a medical procedure such as colonoscopy, or minor or major surgical procedure. As to when exactly to take the last dose of Pradaxa® before the procedure depends on (a) what type of procedure is…
